Matches in Wikidata for { <http://www.wikidata.org/entity/Q90358472> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- Q90358472 description "article scientifique publié en 2018" @default.
- Q90358472 description "artículu científicu espublizáu en xunu de 2018" @default.
- Q90358472 description "scientific article published on 01 June 2018" @default.
- Q90358472 description "wetenschappelijk artikel" @default.
- Q90358472 description "наукова стаття, опублікована в червні 2018" @default.
- Q90358472 name "Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208" @default.
- Q90358472 name "Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208" @default.
- Q90358472 type Item @default.
- Q90358472 label "Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208" @default.
- Q90358472 label "Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208" @default.
- Q90358472 prefLabel "Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208" @default.
- Q90358472 prefLabel "Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208" @default.
- Q90358472 P1433 Q90358472-FED17B51-6CAA-40D1-A9B7-1FE136FD79BA @default.
- Q90358472 P1476 Q90358472-E8612D31-22F7-4013-A738-D5CCEE6E185B @default.
- Q90358472 P2093 Q90358472-2FFA785E-7456-48AF-9511-4BDF543A6063 @default.
- Q90358472 P2093 Q90358472-32BC3858-2623-4859-9B34-08E308D8529D @default.
- Q90358472 P2093 Q90358472-3ECC8FF5-A6E7-4C13-8C1E-D1314C22B053 @default.
- Q90358472 P2093 Q90358472-44746224-FE0A-4C98-AC86-3A65A6A05E81 @default.
- Q90358472 P2093 Q90358472-50FA0C7E-9B45-45F4-A3EE-B133F61AC971 @default.
- Q90358472 P2093 Q90358472-5ABE2D57-1DE0-400F-8083-571C9733724B @default.
- Q90358472 P2093 Q90358472-6868E647-EDE4-4CD7-AE40-31EEABD8DDFF @default.
- Q90358472 P2093 Q90358472-73ACC4DB-D570-484D-8B6B-E9CCB560AA31 @default.
- Q90358472 P2093 Q90358472-C2088CEF-2696-42C0-8AD4-4E0347125BA0 @default.
- Q90358472 P2093 Q90358472-DD53C2D1-F9C3-4F03-ACE8-66D782D437E2 @default.
- Q90358472 P2093 Q90358472-DD839DEE-1D67-42F7-A8CC-0CC5CE60E378 @default.
- Q90358472 P2093 Q90358472-E472E659-240B-48C9-A128-2AC162E14261 @default.
- Q90358472 P304 Q90358472-E51CCF4B-C2C2-4D7E-917A-ACB49ED00199 @default.
- Q90358472 P31 Q90358472-019406F6-15AC-4F2F-AF1F-54D66CCB2E95 @default.
- Q90358472 P356 Q90358472-43B65796-229B-4C9A-9854-12B90EBDD26E @default.
- Q90358472 P478 Q90358472-AF70A274-0BDA-476B-92A8-3462AF50A78E @default.
- Q90358472 P50 Q90358472-341F46F6-3052-4467-8566-3E66F8D77BB5 @default.
- Q90358472 P577 Q90358472-D25068F9-5040-4F42-91C6-33B8A3756AF2 @default.
- Q90358472 P921 Q90358472-2A0C06DC-C8BA-4D1C-B0AE-7FF36D5E6209 @default.
- Q90358472 P921 Q90358472-B0F56C7D-D384-4209-9720-EDFC21328179 @default.
- Q90358472 P921 Q90358472-E2AD2AC7-199F-49C0-A2B4-6FC68F6FBC94 @default.
- Q90358472 P921 Q90358472-F3424EF9-44DE-4B79-98B2-CFBAA5265263 @default.
- Q90358472 P356 MDY149.029 @default.
- Q90358472 P1433 Q326122 @default.
- Q90358472 P1476 "Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208" @default.
- Q90358472 P2093 "Al Bowen Benson" @default.
- Q90358472 P2093 "Bryan Andrew Faller" @default.
- Q90358472 P2093 "Deirdre Jill Cohen" @default.
- Q90358472 P2093 "ECOG-ACRIN" @default.
- Q90358472 P2093 "Edith P Mitchell" @default.
- Q90358472 P2093 "H Hochster" @default.
- Q90358472 P2093 "Jeremy S Kortmansky" @default.
- Q90358472 P2093 "Jill Lacy" @default.
- Q90358472 P2093 "Paul J Catalano" @default.
- Q90358472 P2093 "Peter J O'Dwyer" @default.
- Q90358472 P2093 "Sheetal Mehta Kircher" @default.
- Q90358472 P2093 "Udit N Verma" @default.
- Q90358472 P304 "v110" @default.
- Q90358472 P31 Q13442814 @default.
- Q90358472 P356 "10.1093/ANNONC/MDY149.029" @default.
- Q90358472 P478 "29 Suppl 5" @default.
- Q90358472 P50 Q89668545 @default.
- Q90358472 P577 "2018-06-01T00:00:00Z" @default.
- Q90358472 P921 Q188874 @default.
- Q90358472 P921 Q412197 @default.
- Q90358472 P921 Q420296 @default.
- Q90358472 P921 Q422327 @default.